Objective: To evaluate the effectiveness and reliability of intravitreal bevacizumab in patients with neovascular glaucoma.Material and Methods: Twenty-three eyes of 20 patients who underwent intravitreal bevacizumab for the treatment of neovascular glaucoma in our ophthalmology clinic and were followed for at least 4 months were retrospectively evaluated. Anterior segments were compared using colour image and anterior segment fluorescein angiography before and after injection. Intravitreal bevacizumab of 1.25 mg/0.05 ml was administered to patients who received maximum antiglaucomatous medication prior to the injection. The patients were followed-up on the first day, at the first week, at the first month and then monthly. Results:Of the 20 patients included in the study, 8 were female and 12 were male. The mean age was 65.13±12.31 (24-87) years. The mean follow-up period was 7.44±2.99 (4-10) months. Prior to the injection, 13 eyes (56.52%) underwent panretinal photocoagulation (PRP); 2 eyes (8.69%) cyclocryotherapy; and 1 eye (4.34%) post-operative cryotherapy. In all patients, significant regression of neovascularization was observed in iris and iridocorneal angle within 24 hours after one or two injections. It totally disappeared in 10 eyes (%43.47), including two eyes (%8.69) within 1 week, 8 eyes (%34.78) within 4-6 weeks. Conclusion:Intravitreal bevacizumab injection is an effective method for regressing anterior segment neovascularization. However, methods that permanently inhibit VEGF secretion such as panretinal photocoagulation should also be included in the treatment.
Dry eye is one of the most common ocular diseases in the elderly population and has increasing importance. Aging, decreased hormones and systemic autoimmunity are among the common causes of dry eye disease. Although the etiology of dry eye can change, it is known that the main cause is the inflammation in both lacrimal glands and ocular surfaces. To evaluate the effectiveness of topical cyclosporine A (CsA) 0.05% which is an immunemodulatory agent in the treatment of dry eyes, total of 51 patients with dry eye syndrome were included in our study. Forty-six of the patients were female while 5 patients were male. The mean duration of medication use of the patients was 8.72 ± 3.59 months (6-16 months). There was a statistically significant difference between the pre-treatment Schirmer scores and Schirmer scores found in 1st, 6 th and last month controls of Sjögren and Non-Sjögren groups (p<0.05) while there was no statistically significant difference between Sjögren and Non-Sjögren groups (p>0.05). In conclusion, it was found that there was a significant increase in Schirmer and fluorescein TBUT scores and tear meniscus height of both Sjögren and and Non-Sjögren groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.